HCS technology will be implemented to further advance research capabilities and utilise automated cellular analysis to drive large-scale biology into the laboratory
Cellomics has announced that it has signed a deal with the Mayo Clinic and Foundation in Rochester, Minnesota, that will be led by Franklyn Prendergast.
Dr Prendergast is director of the Mayo Clinic Cancer Center, where Cellomics's high content screening technology will be implemented in order to further advance research capabilities and utilise automated cellular analysis to drive large-scale biology into the laboratory.
The collaboration will provide access to Cellomics's full breadth of products, including the ArrayScan HCS reader, the KineticScan HCS reader, the vHCS Discovery ToolBox and the complete line of proprietary BioApplication software modules for automated cell analyses.
"Cellomics is very proud to announce our second major academic collaboration," stated Lansing Taylor, CEO of Cellomics.
"Dr Prendergast is an outstanding scientist with broad expertise in utilisation of fluorescence-based approaches in his research, and we are excited to be working closely with him and the team of cancer researchers from the Mayo Clinic.
"We fully expect that implementation of Cellomics's HCS platforms will contribute significantly to their ongoing research".
Cellomics continues to demonstrate pioneering advances in the field of cellular knowledge extraction.
Its unique technology, referred to as high content screening, integrates fluorescent reagents, kits, cell lines, multi- parametric BioApplications, HCS instrumentation (both fixed end-point and kinetics systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences.
This automated platform, when applied to lead optimiszation, predictive toxicology, and new target validation, is proving to reduce the '"idea-to-discovery'" cycle time in drug discovery while increasing the probability of the therapeutic success of leads as well as reducing the cycle time in research and similar institutions.
Currently, Cellomics's proprietary ArrayScan and KineticScan HCS readers, along with its vHCS Discovery ToolBox software and proprietary BioApplications, are in use at multiple sites within the top 15 pharmaceutical companies in the world, as well as several additional leading pharmaceutical and biotechnology companies and academic centreglobally.
